Dr
Adam
Hines

Partner

York Office

Engineering

Telephone. +44(0) 1904 732 120
Mobile. +44(0) 776 639 2285
Email. [email protected]

Experience

Adam is a commercially-minded attorney with considerable experience of building, optimizing and defending patent portfolios.

Having previously managed an extensive patent portfolio at a multinational healthcare company, Adam is adept at developing harmonized, robust global IP strategies that complement the commercial goals of his clients and add value to their business.

European patent oppositions are a core aspect of Adam’s work. He has a wealth of knowledge in this area having represented clients at over 50 hearings before the European Patent Office both attacking and defending business-critical patents. Adam enjoys the challenging, dynamic and adversarial nature of the opposition process and has an established track record in achieving favourable outcomes for his clients.

Adam is dedicated to providing insightful and pragmatic advice to clients across a range of different industries and specializes in the field of medical technology and medical devices.

Qualifications

Patent Attorney

Chartered (UK)
European


BSC

Chemistry with Medicinal Chemistry

MSC

Toxicology

PHD

PhD in Biochemistry and Environmental Metabolomics

Publications

Health-conscious IP strategies

View publication online

The Internet of Medical Things

View publication online

Conferences: 2021

November 3rd 2021

Challenging granted patents: a comparison between Europe and the US

Speaker

Event details

June 9th 2021

Webinar: Developing effective patent strategies for personalised medical devices in Europe and the US

Speaker

Event details

January 14th 2021

HGF IP in Healthcare Virtual Conference 2021

Speaker

Event details

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 19th May 2022

HGF Complete webinar: comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

HGF is hosting a series of HGF Complete webinars this Spring. Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.